Adoptive Immunotherapy

Sandra D’Angelo, MD, talked about a study examining the role of tumor-infiltrating lymphocyte, or TIL, in metastatic sarcoma presented at the Connective Tissue Oncology Society Annual Meeting in a video interview.

The FDA granted fast track designation to two oncology therapies.

Most oncology practices deployed immunotherapies as part of their clinical care strategy within 2 years of FDA approval for cancer indications, results of a study in JAMA Oncology showed.

Patrick Hwu, MD, has been appointed president and CEO of Moffitt Cancer Center.

The FDA recently granted its regenerative medicine advanced therapy designation to a chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed or refractory multiple myeloma — an indication that the therapy, called CT053, can address an unmet medical need for patients with the disease.

Phase 1 study of adoptive immunotherapy with CD8+ and CD4+ memory T cells transduced to express an HA-1-specific T cell receptor for children and adults with recurrent acute leukemia after allogeneic hematopoietic stem cell transplantation.

Phase 1 dose-escalation clinical trial to determine the phase 2 dose of autologous TIL 1383I TCR gene-modified T cells using a retrovirus for patients with advanced melanoma.

Aletta Weiss plans to undergo chimeric antigen receptor T-cell treatment for relapsed large B-cell lymphoma, and she’s turning to GoFundMe for help.

As Tom Brokaw eloquently stated, uncertainty is at the heart of the cancer experience for our patients.

In this installment of In Practice, Frederick L. Locke, MD, Co-Leader of the Immunology Program and Director of the Immune Cell Therapy Program at Moffitt Cancer Center, discusses the side effects and toxicities of CAR T-cell treatments. Though he acknowledges they are common, he emphasizes that they should not hinder the referral of patients who are candidates for these potentially ‘lifesaving treatments.’